Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702310 · ClinicalTrials.gov registry record
Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
A clinical trial of Recurrent Mycosis Fungoides and Refractory Mycosis Fungoides, sponsored by Vanderbilt-Ingram Cancer Center.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT02702310 is a study of Recurrent Mycosis Fungoides and Refractory Mycosis Fungoides that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 60 participants, roughly in line with the 56-participant average among 6 other Recurrent Mycosis Fungoides trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT02702310, a study of Recurrent Mycosis Fungoides and Refractory Mycosis Fungoides, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies low- dose total skin electron therapy in treating patients with stage IB-IIIA mycosis fungoides that has not responded to previous treatment (refractory) or has returned after a period of improvement (relapsed). Radiation therapy uses high energy electrons to kill tumor cells and shrink tumors. Rotisserie technique is a method in which the patient receives total skin electron therapy while standing on a rotating platform. Giving low dose total skin electron therapy using rotisserie technique may kill tumor cells, while having fewer side effects, and may allow therapy to be repeated in future if clinically indicated.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Objective Grading of Skin Findings
Study Locations (1)
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-05-22 |
| Est. Completion | 2026-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02702310
The ClinicalTrials.gov registry entry for NCT02702310 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 56-participant average among 6 other Recurrent Mycosis Fungoides trials with a reported enrollment target. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Mycosis Fungoides appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02702310 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT02702310 about?
NCT02702310 is a clinical study titled "Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides". This clinical trial studies low- dose total skin electron therapy in treating patients with stage IB-IIIA mycosis fungoides that has not responded to previous treatment (refractory) or has returned after a period of improvement (relapsed). Radiation therapy uses high energy electrons to kill tumor c...
What is the current status of trial NCT02702310?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2016-05-22. Estimated completion is 2026-09.
What conditions does trial NCT02702310 study?
This clinical trial studies the following conditions: Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Stage I Mycosis Fungoides, Stage II Mycosis Fungoides, Stage III Mycosis Fungoides.
What interventions are being tested in trial NCT02702310?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Objective Grading of Skin Findings (OTHER).
Who is sponsoring clinical trial NCT02702310?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02702310 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Mycosis Fungoides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
RECRUITING
-
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
ACTIVE NOT RECRUITING · Phase 1
-
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
ACTIVE NOT RECRUITING · Phase 1
-
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.